// App-Quantinova.ai

: Early toxicity in a prospective phase I/II trial of MRI-assisted focal boost integrated with HDR monotherapy for low- and intermediate-risk prostate cancer.

Researchers

Presenter

  • Laura D'alimonte

Principal Investigators

  • Joelle Antoine Helou

  • Gerard Morton

  • Hans T. Chung

  • Merrylee McGuffin

  • Ananth Ravi

  • Andrew Loblaw

Medical Centers

  • Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Toronto-Sunnybrook Reg Cancer Centre, Toronto, ON, Canada

  • Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • GATA Binding Protein 3

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • NCT02623933

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved